Biocure Technology Inc. (BICTF)

0.0700 0.0000 (0.00%) At close: 09:30AM EDT

Biocure Technology Inc.

1055 West Hastings Street
Suite 300
Vancouver, BC V6E 2E9
Canada
604-609-7146
https://www.biocuretech.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Björn Cochlovius Ph.D.	President	4.32k	N/A	N/A
Mr. Konstantin Lichtenwald B.B.A., CPA, CGA	CFO, Corporate Secretary & Director	43.88k	N/A	1984
Mr. Yee Sing Cheng	CEO & Director	N/A	N/A	1981
Mr. Marco Nonni	Consultant	12.07k	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

Corporate Governance

Biocure Technology Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.